| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cognition Therapeutics Inc. | CT1812 - (SEQUEL) | Mild-to-Moderate Alzheimer's Disease | Phase 2 | Trial Completed | Oral | Neurology |
| Cognition Therapeutics Inc. | CT1812 - (SNAP) | Alzheimer's Disease | Phase 2 | Trial Completed | oral | Neurology |
| Cognition Therapeutics Inc. | Zervimesine (CT1812) - (START) | Mild Alzheimer's disease | Phase 2 | Enrollment Initiation | oral | Neurology |
| Cognition Therapeutics Inc. | Zervimesine (CT1812) - (SHINE) | Mild-to-Moderate Alzheimer's Disease | Phase 3 | Trial Planned | Oral | Neurology |
| Cognition Therapeutics Inc. | Zervimesine (CT1812) - (SHIMMER) | Dementia with Lewy Bodies (DLB) | Phase 2 | Enrollment Conclusion | oral | Neurology |
| Coherus Oncology Inc. | Toripalimab - (JUPITER-06) | Esophageal Squamous Cell Carcinoma | BLA Filing | Intravenous | Oncology | |
| Coherus Oncology Inc. | Toripalimab - (JUPITER-08) | Extensive stage SCLC | Phase 3 | Intravenous | Oncology | |
| Coherus Oncology Inc. | Toripalimab + platinum-doublet chemotherapy - (NEOTORCH) | NSCLC neoadjuvant setting | Phase 3 | Intravenous | Oncology |